Regulatory submissions for a new subcutaneous (SC) formulation of Takeda Pharmaceutical Co. Ltd.'s blockbuster gastrointestinal drug Entyvio (vedolizumab) in ulcerative colitis (UC) could come in the second half, following positive top-line results from a pivotal trial.
The more convenient formulation met its efficacy endpoint in the 384-patient Phase III VISIBLE 1 placebo-controlled trial, looking at use as a maintenance therapy in adult patients with a moderately...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?